Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
adefovir dipivoxil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| adefovir dipivoxil | DRUG | 10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2) |
| peginterferon alfa-2a [Pegasys] | DRUG | 180 micrograms weekly for 48 weeks |
Inclusion Criteria: * adult patients, 18-70 years of age; * chronic hepatitis B; * positive HBsAg, positive anti-HBe, negative anti HBsAg, negative HBeAg for at least the prior 6 months; * either nucleoside analogue naive, or has not received IFN-a in the past 6 months. Exclusion Criteria: * posi...
Adefovir dipivoxil is an investigational small molecule being studied for the treatment of chronic hepatitis B. It is being developed by Roche Holding AG (ticker: RHHBY). The drug is currently in Phase 3 clinical development for this infectious disease indication.
Adefovir dipivoxil is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug as a treatment for chronic hepatitis B.
Adefovir dipivoxil is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is being studied for chronic hepatitis B.
Adefovir dipivoxil has been studied in one completed Phase 3 trial, NCT00661076, known as the ADVANCE Study. This trial evaluated PEGASYS (peginterferon alfa-2a) plus adefovir dipivoxil in patients with HBe(-) chronic hepatitis B. The trial enrolled 10 participants in Turkey.
Adefovir dipivoxil is a small molecule antiviral agent. It works by inhibiting the activity of viral DNA polymerase, an enzyme essential for hepatitis B virus replication. By blocking this enzyme, the drug interferes with the virus's ability to multiply in the body.